Post-earnings recap
Reported
Thu, Apr 30, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss per share that was slightly worse than expected, contributing to a 7.1% drop in stock price. The absence of revenue figures and guidance may have heightened investor concerns. The company's focus on clinical programs suggests they are prioritizing long-term growth over short-term financial performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | -7.44% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing clinical development despite the lack of financial guidance.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on advancing its clinical programs.